Correcting tumour SUV for enhanced bone marrow uptake: retrospective F-FDG PET/CT studies

Nuclear Medicine Communications

Volumn 29, Issue 4, 2008, Pages 359-366

  Teo, Boon Keng ^a   Badiee, Shiva ^a   Hadi, Mohiuddin ^a   Lam, Tuwin ^a   Johnson, Lauran ^a   Seo, Youngho ^a   Bacharach, Stephen L ^b   Hasegawa, Bruce H ^b   Franc, Benjamin L ^b  

^a Departments of Radiology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone marrow; G CSF; GM CSF; Positron emission; Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; KINETICS; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE MARROW NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 43149091240     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f44f99     Document Type: Article

References (32)

1. Huang SC. Anatomy of SUV. Nucl Med Biol 2000; 27:643-646.
2. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006; 47:1059-1066.
3. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 46:983-995.
4. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44:224-239.
5. Wong CYO, Thie J, Gaskill M, Kestin L, Cheng V, Nagle C. Addressing glucose sensitivity measured by F-18 FDG PET in lung cancers for radiation treatment planning and monitoring. Int J Radiat Oncol Biol Phys 2006; 65:132-137.
6. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin S, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003; 21:1285-1292.
7. Gundlapalli S, Ojha B, Mountz JM. Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med 2002; 27:140-141.
8. Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, et al. Whole body F-18-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20:13-20.
9. Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 2004; 29:161-163.
10. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, et al. Randomized, dose-escalation study of SD/01 compared with daily Filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18:2522-2528.
11. Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake stimulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 1998; 23:93-98.
12. Yao WJ, Hoh CK, Hawkins RA, Glaspy WA, Weil JA, Lee SJ, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995; 36:794-799.
13. Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol 1996; 23:845-849.
14. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth actors: biology and clinical applications. N Engl J Med 1989; 321:1449-1459.
15. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor (1). N Engl J Med 1992; 327:28-35.
16. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor (2). N Engl J Med 1992; 327:99-106.
17. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hermatol 1999; 27:1724-1734.
18. Khan J, Qureshi S, Hickeson M, Badiee S, Cheema J, Sadar R, et al. Pitfalls in F-18 FDG-PET CT: an imaging spectrum. Contemp Diag Radiol 2007; 30:1-5.
19. 18F-FDG: preclinical and clinical studies. J Nucl Med 2006; 47:950-956.
20. Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med 1999; 40:1456-1462.
21. 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med 2007; 48:920-925.
22. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7.
23. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996; 37:950-955.
24. 18F-FDG uptake: a dynamic approach. J Nucl Med 2004; 45:1328-1333.
25. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005; 43:189-204.
26. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-1782.
27. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-flurodeoxyglucose in PET studies. J Nucl Med 1991; 32:699-706.
28. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999; 26:1363-1378.
29. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19:61-77.
30. Taaleb K, Kaiser KP, Wieler H. Elevated uptake of F-18 FDG in PET scans in nonmalignant disease. Clin Nucl Med 2000; 25:939-940.
31. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. Am J Roentgenol 1997; 169:1675-1680.
32. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28:897-916.